A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children

Blood

Volumn 126, Issue 14, 2015, Pages 1651-1657

  Brousseau, David C ^a   Scott, J Paul ^b   Badaki Makun, Oluwakemi ^c   Darbari, Deepika S ^d   Chumpitazi, Corrie E ^e   Airewele, Gladstone E ^e   Ellison, Angela M ^f   Smith Whitley, Kim ^f   Mahajan, Prashant ^g   Sarnaik, Sharada A ^g   Casper, T Charles ^h   Cook, Lawrence J ^h   Dean, J Michael ^h   Leonard, Julie ⁱ   Hulbert, Monica L ^j   Powell, Elizabeth C ^k   Liem, Robert I ^k   Hickey, Robert ^l   Krishnamurti, Lakshmanan ^m   Hillery, Cheryl A ^l   Nimmer, Mark ^a   Panepinto, Julie A ^a   more..

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b BLOOD RESEARCH INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e TEXAS CHILDREN S HOSPITAL   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^g CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^h UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

ⁱ NATIONWIDE CHILDREN S HOSPITAL   (United States)

^j WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k NORTHWESTERN UNIVERSITY   (United States)

^l CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^m EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MAGNESIUM; PLACEBO; NARCOTIC ANALGESIC AGENT; VASODILATOR AGENT;

ACUTE CHEST SYNDROME; ADULT; APPLIED RESEARCH; ARTICLE; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; EMERGENCY; EMERGENCY MEDICINE; FEMALE; GENOTYPE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SICKLE CELL; SICKLE CELL ANEMIA; SICKLE CELL CRISIS; SICKLE CELL PAIN CRISIS; ADOLESCENT; ANEMIA, SICKLE CELL; CLINICAL TRIAL; COMPLICATION; DOUBLE BLIND PROCEDURE; INTRAVENOUS DRUG ADMINISTRATION; PAIN; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ANALGESICS, OPIOID; ANEMIA, SICKLE CELL; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MAGNESIUM; MALE; PAIN; QUALITY OF LIFE; VASODILATOR AGENTS; YOUNG ADULT;

EID: 84947996077     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-05-647107     Document Type: Article

References (41)

1. Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle-cell disease in the United States: national and state estimates. Am J Hematol. 2010;85(1):77-78.
2. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4 Suppl):S512-S521.
3. Panepinto JA, Brousseau DC, Hillery CA, Scott JP. Variation in hospitalizations and hospital length of stay in children with vaso-occlusive crises in sickle cell disease. Pediatr Blood Cancer. 2005;44(2):182-186.
4. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325(1):11-16.
5. Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA. Acute care utilization and rehospitalizations for sickle cell disease. JAMA. 2010;303(13):1288-1294.
6. Panepinto JA, Pajewski NM, Foerster LM, Sabnis S, Hoffmann RG. Impact of family income and sickle cell disease on the health-related quality of life of children. Qual Life Res. 2009;18(1):5-13.
7. Shankar SM, Arbogast PG, Mitchel E, Cooper WO, Wang WC, Griffin MR. Medical care utilization and mortality in sickle cell disease: a population-based study. Am J Hematol. 2005; 80(4):262-270.
8. Dampier CD, Smith WR, Wager CG, et al; Sickle Cell Disease Clinical Research Network (SCDCRN). IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies. Clin Trials. 2013;10(2):319-331.
9. Styles L, Wager CG, Labotka RJ, et al; Sickle Cell Disease Clinical Research Network (SCDCRN). Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE). Br J Haematol. 2012;157(5): 627-636.
10. Peters-Lawrence MH, Bell MC, Hsu LL, et al; Sickle Cell Disease Clinical Research Network (SCDCRN). Clinical trial implementation and recruitment: lessons learned from the early closure of a randomized clinical trial. Contemp Clin Trials. 2012;33(2):291-297.
11. Aslan M, Ryan TM, Adler B, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA. 2001;98(26):15215-15220.
12. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9):886-895.
13. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994; 330(23):1639-1644.
14. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med. 1997; 337(22):1584-1590.
15. Pathare A, Kindi SA, Daar S, Dennison D. Cytokines in sickle cell disease. Hematology. 2003;8(5):329-337.
16. Yang Z-W, Gebrewold A, Nowakowski M, Altura BT, Altura BM. Mg(21)-induced endothelium-dependent relaxation of blood vessels and blood pressure lowering: role of NO. Am J Physiol Regul Integr Comp Physiol. 2000;278(3):R628-R639.
17. Teragawa H, Matsuura H, Chayama K, Oshima T. Mechanisms responsible for vasodilation upon magnesium infusion in vivo: clinical evidence. Magnes Res. 2002;15(3-4):241-246.
18. Teragawa H, Kato M, Yamagata T, Matsuura H, Kajiyama G. Magnesium causes nitric oxide independent coronary artery vasodilation in humans. Heart. 2001;86(2):212-216.
19. Rochelson B, Dowling O, Schwartz N, Metz CN. Magnesium sulfate suppresses inflammatory responses by human umbilical vein endothelial cells (HuVECs) through the NFkappaB pathway. J Reprod Immunol. 2007;73(2):101-107.
20. Weglicki WB, Phillips TM. Pathobiology of magnesium deficiency: a cytokine/neurogenic inflammation hypothesis. Am J Physiol. 1992; 263(3 Pt 2):R734-R737.
21. Wang W, Brugnara C, Snyder C, et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. Br J Haematol. 2011; 152(6):771-776.
22. Hankins JS, Wynn LW, Brugnara C, Hillery CA, Li CS, Wang WC. Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia. Br J Haematol. 2008;140(1):80-85.
23. Brousseau DC, Scott JP, Hillery CA, Panepinto JA. The effect of magnesium on length of stay for pediatric sickle cell pain crisis. Acad Emerg Med. 2004;11(9):968-972.
24. Goldman RD, Mounstephen W, Kirby-Allen M, Friedman JN. Intravenous magnesium sulfate for vaso-occlusive episodes in sickle cell disease. Pediatrics. 2013;132(6):e1634-1641.
25. Badaki-Makun O, Scott JP, Panepinto JA, et al; Pediatric Emergency Care Applied Research Network (PECARN) Magnesium in Sickle Cell Crisis (MAGiC) Study Group. Intravenous magnesium for pediatric sickle cell vaso-occlusive crisis: methodological issues of a randomized controlled trial. Pediatr Blood Cancer. 2014;61(6): 1049-1054.
26. Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med. 1994;330(11):733-737.
27. Orringer EP, Casella JF, Ataga KI, et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial. JAMA. 2001;286(17): 2099-2106.
28. Ruddock B. Chronic pain: switching to an alternate opioid analgesic. Can Pharm J. 2005; 138(1):44-45.
29. Panepinto JA, Pajewski NM, Foerster LM, Hoffmann RG. The performance of the PedsQL generic core scales in children with sickle cell disease. J Pediatr Hematol Oncol. 2008;30(9): 666-673.
30. Panepinto JA, Torres S, Bendo CB, et al. PedsQL™ Multidimensional Fatigue Scale in sickle cell disease: feasibility, reliability, and validity. Pediatr Blood Cancer. 2014;61(1): 171-177.
31. Panepinto JA, Torres S, Bendo CB, et al. PedsQL™ sickle cell disease module: feasibility, reliability, and validity. Pediatr Blood Cancer. 2013;60(8):1338-1344.
32. van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Inst Int Statist. 1960;37(3):351-361.
33. Varni JW. The PedsQLTM 4.0 Measurement Model for the Pediatric Quality of Life InventoryTM Version 4.0: Administration Guidelines. Available at: http://www.pedsql.org/pedsqladmin.html. Accessed January 6, 2015.
34. Varni JW. The PedsQLTM Scoring Algorithm: Scoring the Pediatric Quality of Life InventoryTM. Available at: http://pedsql.org/score.html. Accessed January 6, 2015.
35. De Franceschi L, Bachir D, Galacteros F, et al. Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease. Br J Haematol. 2000;108(2):284-289.
36. Ciarallo L, Brousseau D, Reinert S. Higher-dose intravenous magnesium therapy for children with moderate to severe acute asthma. Arch Pediatr Adolesc Med. 2000;154(10):979-983.
37. Rowe BH, Bretzlaff JA, Bourdon C, Bota GW, Camargo CA Jr. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database Syst Rev. 2000;(2):CD001490.
38. Nath KA, Katusic ZS, Gladwin MT. The perfusion paradox and vascular instability in sickle cell disease. Microcirculation. 2004;11(2):179-193.
39. Maier JA, Malpuech-Brugère C, Zimowska W, Rayssiguier Y, Mazur A. Low magnesium promotes endothelial cell dysfunction: implications for atherosclerosis, inflammation and thrombosis. Biochim Biophys Acta. 2004;1689(1):13-21.
40. Weglicki WB, Phillips TM, Freedman AM, Cassidy MM, Dickens BF. Magnesium-deficiency elevates circulating levels of inflammatory cytokines and endothelin. Mol Cell Biochem. 1992;110(2): 169-173.
41. Jacob E, Miaskowski C, Savedra M, Beyer JE, Treadwell M, Styles L. Quantification of analgesic use in children with sickle cell disease. Clin J Pain. 2007;23(1):8-14.